Encapsulation of a glycosaminoglycan in hydroxyapatite/alginate capsules
Chong Shuan Tan
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorAparna Jejurikar
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorBina Rai
Nanotechnology and Biomaterials Centre, Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorThor Bostrom
Analytical Electron Microscopy Facility, Queensland University of Technology, Brisbane, Queensland 4001, Australia
School of Physical and Chemical Sciences, Queensland University of Technology, Brisbane, Queensland 4001, Australia
Search for more papers by this authorGwen Lawrie
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
Nanotechnology and Biomaterials Centre, Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorCorresponding Author
Lisbeth Grøndahl
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, AustraliaSearch for more papers by this authorChong Shuan Tan
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorAparna Jejurikar
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorBina Rai
Nanotechnology and Biomaterials Centre, Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorThor Bostrom
Analytical Electron Microscopy Facility, Queensland University of Technology, Brisbane, Queensland 4001, Australia
School of Physical and Chemical Sciences, Queensland University of Technology, Brisbane, Queensland 4001, Australia
Search for more papers by this authorGwen Lawrie
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
Nanotechnology and Biomaterials Centre, Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland 4072, Australia
Search for more papers by this authorCorresponding Author
Lisbeth Grøndahl
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland 4072, AustraliaSearch for more papers by this authorAbstract
The development of suitable vehicles for the delivery of growth-inducing factors to fracture sites is a challenging area of bone repair. Bone-specific glycosaminoglycan molecules are of particular interest because of their high stability and proven effect on bone growth. Calcium alginate capsules are popular as delivery vehicles because of their low immunogenic response; they offer a versatile route that enables the controlled release of heparin (a member of the glycosaminoglycan family). In this study, hydroxyapatite (HA)/alginate composite capsules are explored as novel drug delivery vehicles for heparin, using both medium- and low-viscosity alginates. The composition, structure, and stability of the capsules are fully characterized and correlated to the release of heparin in vitro. Heparin is found to associate both with the alginate matrix through polymeric flocculation and also with the HA crystals in the composite beads. The mechanism by which heparin is released is dictated by the stability of the capsule in a particular release media and by the composition of the capsule. The use of medium-viscosity alginate is advantageous with respect to both drug loading and prolonging the release. The inclusion of HA increases the encapsulation efficiency, but because of its destabilizing effect to the alginate hydrogel matrix, it also increases the rate of heparin release. The bioactivity of heparin is fully retained throughout the assembly and release processes. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
References
- 1 Chung YI,Ahn KM,Jeon SH,Lee SY,Lee JH,Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J Control Release 2007; 121: 91–99.
- 2
Chaudhary LR,Avioli LV.
Extracellular-signal regulated kinase signaling pathway mediates downregulation of type I procollagen gene expression by FGF-2, PDGF-BB, and okadaic acid in osteoblastic cells.
J Cell Biochem
2000;
76:
354–359.
10.1002/(SICI)1097-4644(20000301)76:3<354::AID-JCB2>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- 3 Jackson RA,McDonald MM,Nurcombe V,Little DG,Cool SM. The use of heparan sulfate to augment fracture repair in a rat fracture model. J Orthop Res 2006; 24: 636–644.
- 4
Blanquaert F,Barritault D,Caruelle JP.
Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression.
J Biomed Mater Res
1999;
44:
63–72.
10.1002/(SICI)1097-4636(199901)44:1<63::AID-JBM7>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 5 Luong-Van E,Grøndahl L,Nurcombe V,Cool SM. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials 2007; 28: 2127–2136.
- 6 Turnbull J,Powell A,Guimond S. Heparan sulfate: Decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001; 11: 75–82.
- 7 Nurcombe V,Smart CE,Chipperfield H,Cool SM,Boilly B,Hondermarck H. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 2000; 275: 30009–30018.
- 8 Tønnesen HH,Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm 2002; 28: 621–630.
- 9 Rees DA,Welsh EJ. Secondary and tertiary structure of polysaccharides in solution and gels. Angew Chem Int Ed Engl 1977; 16: 214–223.
- 10 Lin HR,Yeh YJ. Porous alginate/hydroxyapatite composite scaffolds for bone tissue engineering: Preparation, characterization, and in vitro studies. J Biomed Mater Res B: Appl Biomater 2004; 71: 52–65.
- 11 Zhang SM,Cui FZ,Liao SS,Zhu Y,Han L. Synthesis and biocompatibility of porous nano-hydroxyapatite/collagen/alginate composite. J Mater Sci Mater Med 2003; 14: 641–645.
- 12 Maruyama M,Terayama K,Ito M,Takei T,Kitagawa E. Hydroxyapatite clay for gap filling and adequate bone ingrowth. J Biomed Mater Res 1995; 29: 329–336.
- 13 Sivakumar M,Panduranga RK Preparation, characterization, and in vitro release of gentamicin from coralline hydroxyapatite-alginate composite microspheres. J Biomed Mater Res A 2003; 65: 222–228.
- 14 Krylova E,Ivanoc A,Orlovski V,El-Registan G,Barivon S. Hydroxyapatite-polysaccharide granules for drug delivery. J Mater Sci Mater Med 2002; 13: 87–90.
- 15 Paul W,Sharma CP. Infection resistant hydroxyapatite/alginate plastic composite. J Mater Sci Lett 1997; 16: 2050–2051.
- 16 Riberio CC,Barrias CC,Barbosa MA. Calcium phosphate-alginate microspheres as enzyme delivery matrices. Biomaterials 2004; 25: 4363–4373.
- 17 Hoffmann M,Huppertz B,Horres R,Keller R,Baumann H. Endothelial cell surface heparan sulfate (ESHS) and synthetic heparin derivatives as hemocompatible coating for biomaterials. Mat wiss u Werkstofftech 2001; 32: 110–115.
- 18 Luong-Van E,Grøndahl L,Chua K,Leong K,Nurcombe V,Cool S. Controlled release of heparin from poly(ε-caprolactone) electrospun fibers. Biomaterials 2006; 27: 2042–2050.
- 19 Grasdalen H,Larsen B,Smidsrød O. A PMR study of the composition and sequence of urinate residues in alginates. Carbohydrate Res 1979; 68: 23–31.
- 20 Tas AC. Synthesis of biomimetic Ca-hydroxyapatite powders at 37 degrees C in synthetic body fluids. Biomaterials 2000; 21: 1429–1438.
- 21 Wei M,Evans JH,Bostrom T,Grøndahl L. Synthesis and characterisation of hydroxyapatite, fluoride-substituted hydroxyapatite and fluorapatite. J Mater Sci Mater Med 2003; 14: 311–320.
- 22 Shilpa A,Agrawal SS,Ray AR. Controlled delivery of drugs from alginate matrix. J Mac Sci Polym Rev 2003; C43: 187–221.
- 23 Lee HJ,Choi HW,Kim KJ,Lee SC. Modification of hydroxyapatite nanosurfaces for enhanced colloidal stability and improved interfacial adhesion in nanocomposites. Chem Mater 2006; 18: 5111–5118.
- 24 Jack KS,Vizcarra TG,Trau M. Characterisation and surface properties of amino-acid-modified carbonate-containing hydroxyapatite particles. Langmuir 2007; 23: 12233–12242.
- 25
Grant GT,Morris ER,Rees DA,Smith PJC,Thom D.
Biological interactions between polysaccharides and divalent cations: Egg-box model.
FEBS Lett
1973;
32:
195–198.
10.1016/0014-5793(73)80770-7 Google Scholar
- 26 Fundueanu G,Nastruzzi C,Carpov A,Desbrieres J,Rinaudo M. Physico-chemical characterization of Ca-alginate microparticles produced with different methods. Biomaterials 1999; 20: 1427–1435.
- 27 Serp D,Mueller M,von Stockar U,Marison W. Low-temperature electron microscopy for the study of polysaccharide ultrastructures in hydrogels. II. Effect of temperature on the structure of Ca2+-alginate beads. Biotechnol Bioeng 2002; 79: 253–259.
- 28 Rees SG,Wassell DTH,Embery G. Interaction of glucoronic acid and iduronic acid-rich glycosaminoglycans and their modified forms with hydroxyapatite. Biomaterials 2002; 23: 481–489.
- 29 Sikorski P,Mo F,Skjåk-Bræk G,Stokke BT. Evidence for egg-box-compatible interactions in calcium-alginate gels from fiber x-ray diffraction. Biomacromolecules 2007; 8: 2098–2103.
- 30
Chevalier F,Angulo J,Lucas R,Nieto PM,Martin-Lomas M.
The heparin-Ca2+ interaction: Structure of the Ca2+ binding site.
Eur J Org Chem
2002;
14:
2367–2376.
10.1002/1099-0690(200207)2002:14<2367::AID-EJOC2367>3.0.CO;2-K Google Scholar
- 31
Grant D,Moffat CF,Long WF,Williamson FB.
Optical rotation changes in chemically modified heparins as a guide to anionic groups involved in calcium binding.
Biochem Soc Trans
1991;
19:
S393.
10.1042/bst019393s Google Scholar
- 32 Arica B,Calis S,Kas HS,Sargon MF,Hincal AA. 5-Flurouracil encapsulated alginate beads for the treatment of breast cancer. Int J Pharm 2002; 242: 267–269.
- 33 Martell AE,Smith RM. Critical Stability Constants. New York: Plenum Press; 1974.
- 34 Kokubo T,Kushitani H,Sakka S,Kitsugi T,Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W. J Biomed Mater Res 1990; 24: 721–734.
- 35 Misra DN. Adsorption of polyacrylic acids and their sodium salts on hydroxyapatite: Effect of relative molar mass. J Colloid Interface Sci 1996; 181: 289–296.
- 36 Malkaj P,Pierre E,Dalas E. The crystallization of Hydroxyapatite in the presence of sodium alginate. J Mater Sci Mater Med 2005; 16: 733–737.
- 37 Downs EC,Robertson NE,Riss TL,Plunkett ML. Calcium alginate beads as slow-release system for delivering angiogenic molecules in vivo and in vitro. J Cell Physiol 1992; 152: 422–429.
- 38 Bowersock TL,HogenEsch H,Suckow M,Porter RE,Jackson R,Park H,Park K. Oral vaccination with alginate microsphere systems. J Control Release 1996; 39: 209–220.
- 39 Yasuhiko T. Tissue regeneration based on growth factor release. Tissue Eng 2003; 9: S5–S15.
- 40 Gu F,Amsden B,Neufeld R. Sustained delivery of vascular endothelial growth factor with alginate beads. J Control Release 2004; 96: 463–472.
- 41 Fathy M,Safwat SM,El-Shanawany SM,Shawky Tous S,Otagiri M. Preparation and evaluation of beads made of different calcium alginate compositions for oral sustained release of tiaramide. Pharm Dev Tech 1998; 3: 355–364.
- 42 Ho J,Neufeld RJ. Retention and release of low molecular weight DNA from alginate beads. STP Pharma Sci 2001; 11: 109–115.
- 43 McLennan G,Johnson MS,Stookey KR,Zhang Z,Fife WK. Kinetics of release of heparin from alginate hydrogel. JVIR 2002; 11: 1087–1094.
- 44 Douglas KL,Tabrizian M. Effect of experimental parameters on the formation of alginate-chitosan nanoparticles and evaluation of their potential application as DNA carrier. J Biomater Sci Polymer Ed 2005; 16: 43–56.
- 45 Chandy T,Rao GHR,Wilson RF,Das GS. Delivery of LMW Heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv 2002; 9: 87–96.
- 46 Hoffman AS. Hydrogels for biomedical applications. Adv Drug Del Rev 2002; 43: 3–12.
- 47 Mizushima Y,Ikoma T,Tanaka J,Hoshi K,Ishihara T,Ogawa Y,Ueno A. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J Control Release 2006; 110: 260–265.
- 48 Gbureck U,Vorndran E,Müller FA,Barralet JE. Low temperature direct 3D printed bioceramics and biocomposites as drug release matrices. J Control Release 2007; 122: 173–180.
Citing Literature
